Dr. Sara Sdelci is a leading cancer epigenetics researcher and a pioneer in defining nuclear cancer metabolism as a new field linking metabolic activity to chromatin regulation and tumour identity. Trained at IRB Barcelona and later at CeMM (Vienna), her discoveries have uncovered novel therapeutic vulnerabilities and clinically relevant biomarkers.

Since 2019 she has led her own laboratory, first at the CRG and soon at CIC bioGUNE, where she produced advances such as the chromatome atlas and several precision-oncology patents. She has secured over €3.5 million in competitive funding, including an ERC Starting Grant, and established high-impact international collaborations. Her work positions her among the most influential scientists at the interface of metabolism and cancer epigenetics.